Endocrinology Vol. 142, No. 4 1479-1488
Copyright © 2001 by The Endocrine Society
Inability of Overexpressed des(13)Human Insulin-Like Growth Factor I (IGF-I) to Inhibit Forced Mammary Gland Involution Is Associated with Decreased Expression of IGF Signaling Molecules1
Darryl L. Hadsell,
Tatiana Alexeenko,
Yann Klemintidis,
Daniel Torres and
Adrian V. Lee2
Department of Pediatrics, U.S. Department of
Agriculture/Agricultural Research Service Childrens Nutrition
Research Center (D.L.H., T.A., Y.K., D.T.); and Breast Center,
Department of Medicine (A.V.L.), and Department of Molecular and
Cellular Biology (D.L.H., A.V.L.), Baylor College of Medicine, Houston,
Texas 77030
Address all correspondence and requests for reprints to: Dr. Darryl L. Hadsell, Department of Pediatrics, U.S. Department of Agriculture (USDA)/Agrucultural Research Service (ARS) Childrens Nutrition Research Center, Houston, Texas 77030. E-mail:
dhadsell{at}bcm.tmc.edu
 |
Abstract
|
|---|
Overexpression of des(13) human insulin-like growth factor I (IGF-I)
in the mammary glands of transgenic mice (WAP-DES) inhibits apoptosis
during natural, but not forced, mammary involution. We hypothesized
that this differential response would correlate with the expression of
IGF signal transducers. Forced and natural involution were analyzed in
nontransgenic and WAP-DES mice beginning on day 16 postpartum. During
natural involution, mammary gland wet weight was higher and apoptosis
was lower in WAP-DES than in nontransgenic mice. The WAP-DES transgene
had no effect on these parameters during forced involution. Mammary
tissue concentrations of the transgene protein were 2- to 10-fold
higher than those of endogenous IGF-I. Western blot analysis of pooled
mammary tissue extracts demonstrated only slightly higher
phosphorylation of the IGF signal transducers insulin receptor
substrate-1 (IRS-1) and Akt in the WAP-DES than in nontransgenic mice.
Dramatic early reductions in phospho-IRS-1, phospho-Akt, IRS-1, IRS-2,
and Akt proteins occurred during forced, but not natural, involution.
The abundance of the IGF-I receptor and the messenger RNAs for the
IGF-I receptors, IRS-1 and -2, were not affected by either genotype or
involution. These findings support the conclusions that mammary cells
lose their responsiveness to insulin-like signals during forced
involution, and that posttranscriptional or posttranslational
regulation of IRS-1 and IRS-2 may play a role in this loss.
 |
Introduction
|
|---|
IN MICE, MAMMARY gland involution begins to
occur naturally between days 16 and 19 of lactation (1).
This occurs through increased mammary cell apoptosis, which is induced
in response to decreased removal of milk by the suckling pups. This
process has been extensively studied using an experimental paradigm
described as forced involution (2). In this paradigm,
mammary involution is intentionally induced by removal of the suckling
pups at peak lactation. Forced mammary gland involution occurs in two
distinct stages (3). During stage 1, engorgement of the
gland with milk is associated with increased epithelial apoptosis and
decreased expression of milk protein genes. This stage is also
characterized by dramatic increases in the expression of Bcl-2 homology
proteins (4), transcription factors (2), and
cell cycle regulators (5). The second stage of forced
involution is characterized by increased expression and activity of
proteases and intensive tissue remodeling (3). These
dramatic changes in gene expression and cellular apoptosis are believed
to result from the loss of local trophic factors in response to milk
stasis (1). These factors include PRL, glucocorticoids,
and insulin-like growth factor I (IGF-I) (6, 7, 8). For
IGF-I, this loss is hypothesized to be a consequence of increased
expression of IGF-binding proteins that bind IGF-I and reduce
bioavailability (8, 9, 10). However, in addition to the loss
of extracellular trophic signals, decreased cellular responsiveness to
these signals may be a mechanism for induction of apoptosis during
mammary gland involution. Studies in cell culture models suggest that
the abundance and/or activation of the intracellular IGF/insulin signal
transducer insulin receptor substrate-1 (IRS-1) determines the ability
of IGF-I and/or insulin to protect cells from apoptosis (11, 12). This protective effect is known to occur through activation
of PI3-kinase and Akt, followed by phosphorylation-dependent
inactivation of the proapoptotic BH protein, Bcl-associated death
promoter (BAD) (13).
Overexpression of wild-type IGF-I in the mammary glands of transgenic
mice has been demonstrated to inhibit apoptosis when analyzed on day 5
of forced involution (14). Studies in our own laboratory
have shown that overexpression of the des(1, 2, 3) truncated form of IGF-I
under control of the promoter from the rat whey acidic protein gene
(WAP-DES) inhibits the apoptosis that occurs during natural mammary
involution and increases the frequency of spontaneous mammary tumors
(15, 16). However, preliminary studies in our laboratory
suggested that WAP-DES was incapable of inhibiting apoptosis during
forced involution. The goals of the current study were, therefore, 1)
to characterize in greater detail the ability of overexpressed
des(13])human (h) IGF-I to inhibit apoptosis during forced
vs. natural mammary gland involution, and 2) to determine
whether expression of IGF signal transducers could account for
differential responsiveness of the involuting mammary gland to
overexpressed des(1, 2, 3)hIGF-I.
 |
Materials and Methods
|
|---|
Animals
The transgenic mice used in these studies were FVB mice carrying
the previously described WAP-DES transgene (15). These
animal studies were conducted using procedures outlined in the NIH
Guide to Care and Use of Experimental Animals and were approved by the
Baylor College of Medicine animal care and use committee. Nontransgenic
(n = 36) and WAP-DES (n = 39) mice were allowed to complete a
normal pregnancy. For the purposes of this study, the day of
parturition is referred to as day 0. On day 2 postpartum, the litter
size of each dam was adjusted to 10 by cross-fostering. Natural
involution was studied in mammary tissue samples collected on days 16,
18, 20, and 22 postpartum. Forced involution was induced by removal of
the pups on day 16 and studying tissue samples collected on days 1720
postpartum. Mammary glands were collected from each mouse and either
snap-frozen in liquid nitrogen or fixed in 10% neutral buffered
formalin and processed for immunohistochemistry. Mammary gland wet
weight was estimated from one of the number four mammary glands.
Histology
Tissue was fixed and processed for immunohistochemistry
(15). Mammary tissue sections were stained for apoptosis
using a previously described (17) modification of the
terminal deoxynucleotidyltransferase-mediated deoxy-UTP nick end
labeling (TUNEL) technique (18). Labeling indexes were
obtained by counting labeled and unlabeled epithelial cells in 812
(
1000 cells total) fields at x1000 magnification.
Immunohistochemistry for IRS-1 was conducted on paraffin-embedded
sections of mammary tissue using a rabbit antihuman IRS-1 antibody
(Upstate Biotechnology, Inc., Lake Placid, NY). All
incubations were performed at room temperature, and all washing was
performed with 0.15 M NaCl, 0.01 M Tris-HCl (pH
7.4), and 0.05% Tween 20 unless otherwise stated. Slides were cut at
34 µm, baked overnight at 58 C, and deparaffinized using a
Shandon-Lipshaw Varistain (program 2) (Shandon Inc., Pittsburgh,
PA). Heat-induced antigen retrieval was performed in 0.1 M
Tris-HCl (pH 9.0) for 5 min. Endogenous peroxidase activity was blocked
by incubation in 3% hydrogen peroxide solution for 5 min.
Avidin/biotin blocking was performed with the A/B blocking kit
(Vector Laboratories, Inc., Burlingame, CA) by incubation
in solution A for 15 min and then in solution B for 15 min. Slides were
then incubated in IRS-1 antibody (1:800 dilution in TBS plus 1% BSA)
for 1 h, biotin-labeled secondary antibody (1:200) for 30 min, and
horseradish peroxidase-labeled avidin (1:200) for 30 min. For a
negative control, slides were incubated with purified rabbit Ig
(Jackson ImmunoResearch Laboratories, Inc., West Grove,
PA). Detection was then performed by incubation with diaminobenzidine
(DAKO Corp., Carpinteria, CA) for 15 min, followed by
enhancement with 0.2% osmium tetroxide for 30 sec. Slides were
counterstained with 0.05% methylene green for 30 sec, dehydrated, and
mounted using cytoseal. For detection of steroid hormone receptors we
used the same method with antibodies to estrogen receptor
(6F11,
Vector Laboratories, Inc.) and progesterone receptor
(1294, DAKO Corp.).
RNA analysis
Total RNA was isolated from about 100 mg tissue using Ultraspec
(Biotecx, Houston, TX) as described by the manufacturer. Ribonuclease
protection assays (RPA) were used to analyze the abundance of the
messenger RNAs (mRNAs) for IGF-I receptor (IGF-IR), IRS-1, and IRS-2.
The RPA probe for murine IGF-IR has been previously described
(16). The probes for murine IRS-1 and -2 were produced by
cloning PCR fragments amplified from mouse genomic DNA. For the murine
IRS-1 probe, pDT1-mIRS-1, a 447-bp PCR product, was amplified with the
forward and reverse primers, 5'-CAT CCG AAT TCA CCT GCG CAA GCC CAA GAG
T-3' and 5'-AAA GAG GAT CCT GCC AGA CCT CCT TGA ACG C-3', respectively.
For the murine IRS-2 probe, pDT1-mIRS-2, a 329-bp PCR product, was
amplified with the forward and reverse primers, 5'-GGT AAG AAT TCA GGA
CCT TCC CAG TAA ACG G-3' and 5'-AAT AAG GAT CCT GGT CAT TGT CTC CGC TGC
A-3', respectively. The temperature-time settings for these 30 cycle
amplifications were 95 C for 1 min, 65 C for 2 min, and 72 C for 3 min.
The resulting products were digested with EcoRI and
BamHI and then ligated into the corresponding sites in
pBluescript (Stratagene, La Jolla, CA). The
pTRI-cyclophilin-mouse antisense control template (Ambion, Inc., Austin, TX) was used to measure cyclophilin mRNA as a
loading control. Antisense complementary RNAs were produced using T3
RNA polymerase and resulted in probes of 502, 384, and 138 nucleotides
(nt) for IRS-1 IRS-2, and cyclophilin, respectively. RPAs were
conducted using the RPA III kit (Ambion, Inc.).
Quantitative data were obtained using the Storm PhosphorImager
(Molecular Dynamics, Inc., Sunnyvale, CA.)
IGF-I measurement
Acetic acid extracts (19) of mammary tissue were
assayed for both human IGF-I and mouse IGF-I using species-specific
assay kits (Diagnostics Systems Laboratories, Inc.,
Webster, TX). For the human IGF-I assay, approximately 50 mg frozen
mammary tissue were removed from liquid nitrogen and immediately
homogenized in 2 ml ice-cold 1 M acetic acid. Tissue
extracts prepared from this homogenate were neutralized by diluting 1:6
in a neutralization buffer provided with the assay kit and then diluted
in the assay zero standard. This assay had a working range of 0.1520
ng/ml and a minimum detection limit of 36 ng/g tissue. The intraassay
coefficient of variation was 6%. The specificity of the assay for the
human IGF-I transgene product was evident by the fact that parallel
analysis of mammary tissue extracts prepared from nontransgenic mice
failed to give a signal above the zero assay standard (data not shown).
For analysis of mouse IGF-I, mammary tissue was homogenized in 5 vol 1
M acetic acid. Extracts were than neutralized as described
above. The rodent-specific RIA had a working range of 5.3133 ng/ml
and a minimum sensitivity of 114 ng/g tissue. The intraassay
coefficient of variation was 4%.
Western blotting
Mammary tissue extracts were prepared for protein analysis as
previously described (20). For each genotype time point,
equivalent amounts of protein from four individual mammary gland
extracts were pooled. Immunoprecipitations for IRS-1 and IRS-2 were
conducted using 5 µg of each antibody (Upstate Biotechnology, Inc., Lake Placid, NY) and 500 µg of protein from each pool as
previously described (20). These immunoprecipitates were
then resolved by 8% SDS-PAGE and blotted to nitrocellulose
(Schleicher & Schuell, Inc., Keene, NH). The resulting
blots were analyzed for phosphotyrosine as previously described
(20). Equal protein concentrations of the pooled extracts
(10100 µg depending upon the antigen to be detected) were also
directly electrophoresed on 8% SDS-PAGE gels and used for Western blot
analysis. Equal protein loading was assessed after electrophoretic
transfer by staining the membrane in 0.1% Ponceau S in 5% acetic acid
(Sigma, St. Louis, MO) for 5 min. Blots generated with
these extracts were probed with antibodies specific to IGF-IR (1:1000;
-IR3, Calbiochem, San Diego, CA), IRS-1 (1:1000;
Upstate Biotechnology, Inc.), IRS-2 (1:1000; Upstate Biotechnology, Inc.), p85 subunit of phosphatidylinositol-3
kinase (1:2000; Upstate Biotechnology, Inc.), phospho-Akt
(1:1000; New England Biolabs, Inc., Beverly, MA), total
Akt (1:1000; New England Biolabs, Inc.), phospho-BAD
(1:1000; Upstate Biotechnology, Inc.), and total BAD
(1:1000; Santa Cruz Biotechnology, Inc., Santa Cruz, CA)
using previously described procedures (20). The blots were
also probed with an antibody to keratin 18 (K18, Progen Biotechnik,
Heidelberg, Germany) to examine epithelial content.
Autoradiograms were generated by exposing the blots for varying times
from 10 sec to 30 min. The resulting autoradiograms were scanned on the
Personal Densitometer SI (Molecular Dynamics, Inc.,
Sunnyvale, CA) to provide quantitative data. For Quantitative
comparison of IRS and Akt, exposure times were chosen that allowed for
the detection of signals with the least abundance. The data were
expressed as the integrated area under the curve, assuming equivalent
loading based Ponceau S staining and the bicinchoninic acid protein
assay (20).
Statistics
Quantitative data on mammary tissue weight, apoptosis, and
hIGF-I concentration were analyzed using the general linear models
procedure in SPSS for Windows version 10.0.0 (SPSS, Inc.,
Chicago, IL). The effects of involution and genotype on K18,
phospho-Akt and total Akt were determined by one-way ANOVA on data
collapsed for day within each genotype/involution combination. This was
done because there was no apparent effect of day of Akt phosphorylation
and abundance. Decreased apoptosis or increased mammary gland weight in
the WAP-DES mice on individual days was tested for using a one-way
unpaired t test. Differences were considered significant at
P < 0.05.
 |
Results
|
|---|
Preliminary analysis of the WAP-DES transgenic mice has
demonstrated that overexpressed des(1, 2, 3)IGF-I can inhibit apoptosis
during natural, but not forced, mammary gland involution. To analyze in
detail this differential effect, cohorts of nontransgenic or WAP-DES
mice were sampled on several days during either natural or forced
mammary involution. During the 6 days that natural involution was
studied, mammary gland wet weight declined in the nontransgenic mice by
53%, indicating that tissue loss and/or decreased milk synthesis were
occurring (Fig. 1A
). In contrast, the
decline in mammary gland weight in the WAP-DES mice was delayed by 2
days, and hence, tissue weight was maintained at 2930% greater than
that of nontransgenic mice (P < 0.05). Analysis of
mammary tissue apoptosis during natural involution (Fig. 1B
) revealed
only 0.20.3% apoptosis in nontransgenic and WAP-DES mice on day 16
postpartum. By day 20 postpartum, this value increased 14-fold to
2.8 ± 0.6% in the nontransgenic mice. In contrast, mammary
tissue apoptosis in the WAP-DES mice on day 20 postpartum, although
increased to 1.4 ± 0.3%, was only 51% of that observed in the
nontransgenic animals (P < 0.05). By day 22
postpartum, mammary tissue apoptosis in the WAP-DES mice was still only
61% of that observed in the nontransgenic mice (P <
0.05). Thus, des(1, 2, 3)hIGF-I overexpression inhibited apoptosis during
natural involution of the mammary gland.

View larger version (28K):
[in this window]
[in a new window]
|
Figure 1. Analysis of mammary gland weight (A and C) and
apoptosis (B and D) during either natural (A and B) or forced (C and D)
involution. Lactating nontransgenic () or WAP-DES ( ) mice were
placed with litters of 10 pups each at 2 days postpartum. At days 16,
18, 20, and 22 postpartum, mammary glands were collected for analysis
of natural involution. Forced involution was induced at day 16
postpartum. Mammary tissue samples were then collected at days 17, 18,
19, and 20 postpartum. Wet weight was measured on one of the number 4
mammary glands. Apoptosis was detected by TUNEL staining and was
enumerated by counting positive and negative cells in 10 randomly
chosen x100 fields. *, P < 0.05.
|
|
During forced involution, mammary gland wet weight in nontransgenic and
WAP-DES mice displayed similar changes (Fig. 1C
), with an initial,
transient increase due to milk accumulation followed by weight loss
toward the end of the 4-day time period. Mammary cell apoptosis also
underwent similar changes between nontransgenic and WAP-DES mice during
forced involution (Fig. 1D
), supporting the conclusion that
overexpression of des(1, 2, 3)hIGF-I does not inhibit the apoptosis that
occurs during the first 4 days of forced involution.
A decreased transgene expression and lower abundance of the transgene
protein during forced involution would explain the inability of WAP-DES
to protect mammary cells from apoptosis. To test this hypothesis,
species-specific assays were used to measure both human and mouse IGF-I
in mammary tissue extracts from WAP-DES and nontransgenic mice during
natural and forced mammary involution (Fig. 2
). At 16 days postpartum, the
concentration of des(1, 2, 3)hIGF-I in mammary tissue from the WAP-DES
mice averaged 1090 ± 1038 ng/g tissue (Fig. 2A
). During natural
involution, these concentrations gradually increased to a maximum of
4012 ± 233 ng/g tissue on day 22. In contrast, the concentration
of endogenous IGF-I was below the detection limit of 114 ng/g tissue
for both nontransgenic and WAP-DES mice throughout the course of
natural involution. The concentration of des(1, 2, 3)hIGF-I in the mammary
tissue of WAP-DES mice during forced involution ranged from a high of
1599 ± 410 ng/g tissue on day 17 to 969 ± 292 ng/g tissue
on day 20 postpartum (Fig. 2B
). During forced involution,
concentrations of endogenous IGF-I ranged from below the limit of
detection on day 17 to as much as 402 ± 37 ng/g tissue on day 18
postpartum. The concentration of endogenous IGF-I during forced
involution was also slightly, but significantly (P <
0.05), lower in mammary tissue from WAP-DES compared with nontransgenic
mice. No significant differences were observed in des(1, 2, 3)hIGF-I
concentrations among the first three time points of natural involution
(days 16, 18, and 20) and forced involution (days 17 18, and 19). This
is the time when significant differences were observed in apoptosis and
wet weight between nontransgenic and WAP-DES mice (see Fig. 1
) during
natural, but not forced, involution.
To determine whether the apparent lack of responsiveness to WAP-DES was
due to loss of IGF-IR expression, the abundance of both IGF-IR protein
and mRNA was examined. Western blot analysis for IGF-IR ß-subunit
detected the 97-kDa subunit at variable levels in the pooled extracts
from both nontransgenic and WAP-DES mammary glands (Fig. 3A
). The receptor protein, however, was
not diminished by forced mammary involution. The variation observed in
the abundance of the receptor also showed little apparent relationship
to genotype. Western blotting for K18 demonstrated variation unrelated
to genotype or involution. This was repeatedly found with all of the
blots in which K18 was measured (see also Figs. 4
and 7
). Furthermore, statistical
analysis of the densitometry data from all three K18 blots failed to
detect a significant change in response to either genotype or
involution (data not shown). Ribonuclease protection analysis
demonstrated that the abundance of the IGF-IR mRNA was not diminished
by forced involution and was little affected by the WAP-DES transgene
(Fig. 3B
).

View larger version (89K):
[in this window]
[in a new window]
|
Figure 3. Expression of the IGF-IR during mammary gland
involution. Western blot analysis of IGF-IR (A) abundance in mammary
tissue extracts prepared from either nontransgenic (lanes 37 and
1316) or WAP-DES (lanes 812 and 1720) mice during either natural
(lanes 312) or forced (lanes 1320) involution. Each lane contains
equal amounts of protein (100 µg/lane) from a pooled extract
representing four individual mice. Protein extracts from MCF-7 cells
cultured in the absence or presence of IGF-I (40 ng/ml) for 15 min
serve as positive controls and are in lanes 1 and 2, respectively. The
blots were also probed for K18 to determine epithelial content. No
signal was observed for K18 in lanes 19 and 20 due to a localized
transfer problem. The results of ribonuclease protection analysis of
the IGF-IR mRNA (B) in total RNA prepared from mammary tissue of either
nontransgenic (lanes 14 and 912) or WAP-DES (lanes 58 and 1316)
mice during either natural (lanes 18) or forced (lanes 916) are
shown. Each lane contains 20 µg RNA from a pooled RNA sample
representing a minimum of four mice. Total RNA prepared from kidney
served as a positive control (lane 17). Yeast RNA served as a negative
control (lane 18). The undigested probe is in lane 19. The sizes of the
undigested probe fragments was 362 and 168 nt for the IGF-IR and
cyclophilin probes, respectively. On digestion of the RPA reactions
with ribonuclease, protected fragments of 302 and 103 nt were generated
for IGF-IR and cyclophilin mRNAs, respectively.
|
|
To determine whether the inability of overexpressed IGF-I to inhibit
apoptosis was associated with diminished IGF-IR signaling capacity,
phosphorylation of IRS-1 and -2 was examined (Fig. 4
). Western blot
analysis of immunoprecipitates prepared from pooled mammary tissue
extracts demonstrated abundant tyrosine phosphorylation of IRS-1
(Py-IRS-1) during natural involution (Fig. 4A
, lanes 312). The degree
of IRS-1 phosphorylation appeared to be slightly higher in pooled
extracts from the WAP-DES mice on days 20 and 22 than in the
nontransgenic (compare lanes 6 and 7 with 11 and 12 in Fig. 4A
). This
effect, however, was not dramatic. During forced involution,
phosphorylation of IRS-1 was detected only in the day 17 nontransgenic
pool (Fig. 4A
, lane 15). Phosphorylation of IRS-2 (Py-IRS-2) was not
detected during natural involution, but was present at detectable, but
low, levels in some of the pools obtained from mammary tissue during
forced involution (Fig. 4A
, lanes 1522). Western blot analysis
demonstrated abundant IRS-1 and -2 protein during natural involution in
mammary gland extracts from both nontransgenic (Fig. 4A
, lanes 37)
and WAP-DES (Fig. 4A
, lanes 812) mice. The abundance of these two
proteins was similar between nontransgenic and WAP-DES mice on days
818 postpartum. Both IRS-1 and -2 decreased on days 20 and 22
postpartum (Fig. 4A
, lanes 6, 7, 11, and 12). For IRS-1, this decrease
was slightly greater for the nontransgenic mice than for the WAP-DES
mice. For IRS-2, the decrease appeared to be delayed 1 day in WAP-DES
compared with nontransgenic mice. For both proteins, however, the
apparent effect of the transgene was relatively small compared with the
effect of forced involution. Consequently, the densitometric data from
the IRS-1 and -2 blot were pooled across genotype, as presented in Fig. 4
, B and C.
Abundance of IRS-1 and -2 decreased over the course of natural
involution by 70% and 93%, respectively (Fig. 4B
). For IRS-1, the
decrease occurred gradually throughout the course of natural
involution. For IRS-2, the decrease was only apparent on days 20 and 22
when apoptosis was increased. During forced mammary involution, a
dramatic reduction in IRS-1 and -2 protein abundance preceded the onset
of apoptosis in both the nontransgenic and WAP-DES mice (Fig. 4A
, lanes
1522). On day 17 postpartum, after only 24 h of forced
involution, mammary gland IRS-1 and -2 abundance was reduced by 54%
and 96% compared with that on day 16 of lactation (Fig. 4
, B and C).
By day 18 postpartum, IRS-1 was reduced by 97%, and IRS-2 was
undetectable. Reprobing the same blots with antibodies to the p85
regulatory subunit of phosphatidylinositol 3-kinase (PI3 kinase)
and K18 demonstrated little effect of genotype or mammary gland
involution (Fig. 4A
) on the abundance of these two proteins. The
decrease in IRS-1 protein abundance during forced involution was
confirmed by immunohistochemical staining of mammary tissue sections
(Fig. 5
). Intense cytoplasmic IRS-1
staining was observed in the mammary epithelial cells of nontransgenic
mice undergoing natural involution (Fig. 5A
). In the absence of primary
antibody, only a low level of background staining was detected (Fig. 5
, B and D). In mammary epithelial cells of mice undergoing forced
involution, the intensity of IRS-1 staining was reduced to near
background levels (Fig. 5C
). Loss of IRS-1 and -2 proteins during
forced involution has also been observed in a separate series of
studies on developmental regulation of these proteins during a complete
lactational cycle (Lee, A.V., and D. L. Hadsell, unpublished
observations). These data support the hypothesis that decreased IRS-1
and -2 expression in the epithelium is associated with an inability of
overexpressed des (1, 2, 3)hIGF-I to inhibit mammary gland apoptosis
during forced involution.

View larger version (144K):
[in this window]
[in a new window]
|
Figure 5. Immunohistochemical detection of IRS-1 protein in
mammary tissue sections from mice during mammary involution. Mammary
tissue sections from nontransgenic mice undergoing either natural (A
and B) or forced (C and D) mammary involution were stained with
anti-IRS-1 antibody at a dilution of 1:800. The images were captured at
a magnification of x400 and are representative of four mice each.
Exclusion of the primary antibody from the staining reactions served as
a negative control (B and D). A, The arrows illustrate
IRS-negative mammary epithelial cell nuclei that are surrounded by
intensely IRS-1-positive cytoplasm.
|
|
We and others have shown that steroid hormones can increase IRS-1 and
IRS-2 mRNA levels (20, 21). We therefore examined whether
the change in IRS expression during involution was paralleled by a loss
of steroid hormone receptor expression [estrogen receptor (ER) or
progesterone receptor (PR)]. We, therefore, immunostained mammary
tissue sections from nontransgenic mice on days 8, 16, and 22
postpartum. Nuclear staining of ER and PR was readily detectable in
both mammary gland and ovarian tissue from 6-week-old virgin mice. In
contrast, ER and PR levels were low or undetectable in mammary gland
sections from mice on 8, 16, and 22 days postpartum (data not shown).
Furthermore, no change in ER or PR expression was seen in mammary
glands on days 8, 16, and 22 postpartum. To determine whether the
decreased abundance of IRS proteins was due to decreased mRNA
abundance, RPA assays were conducted on pools of RNA prepared from
mammary tissue of nontransgenic or WAP-DES mice during either natural
or forced involution (Fig. 6
). The
results of this analysis demonstrated that the changes in IRS protein
levels during involution occurred independently of ER and PR status,
and that the abundance of the IRS-1 and -2 mRNAs was similar between
nontransgenic and WAP-DES mice and did not change in response to
natural or forced involution.

View larger version (80K):
[in this window]
[in a new window]
|
Figure 6. Abundance of IRS-1 and -2 mRNA during mammary
involution. Ribonuclease protection analysis of the IRS-1 and -2 mRNA
was conducted in total RNA pools prepared from mammary tissue of either
nontransgenic (lanes 14 and 912) or WAP-DES (lanes 58 and 1316)
mice during either natural (lanes 18) or forced (lanes 916)
involution. Each lane contains 40 µg RNA from a pooled RNA sample
representing a minimum of four mice. Total RNA prepared from mouse
liver served as a positive control (lane 17). Yeast RNA served as a
negative control (lane 18). The undigested probe is in lane 19. The
expected sizes of the undigested probes are 502, 384, and 168 nt for
IRS-1, IRS-2 and cyclophilin, respectively. The expected sizes of the
protected fragments are 447, 329, and 103 for IRS-1, IRS-2, and
cyclophilin, respectively.
|
|
Activation of cell survival has, in some models, been demonstrated to
occur through an IRS/PI3 kinase-dependent activation of Akt (12, 22, 23). To determine whether activation and/or expression of
Akt were related to the ability of IGF-I to protect the mammary gland
from apoptosis, both phospho-Akt and total Akt were measured by Western
blotting. Phosphorylated Akt was detectable in extracts prepared from
mammary tissue obtained during both natural (Fig. 7A
, lanes 311) and forced (Fig. 7A
, lanes 1219) involution. The abundance of phospho-Akt was dramatically
reduced with forced involution. In addition, there appeared to be
moderate enhancement of phospho-Akt in extracts prepared from WAP-DES
mice during forced involution compared with that in nontransgenic mice.
These results were obtained in two separate sets of gels run with two
independently prepared sets of extracts. In both sets of extracts there
was no apparent effect of day of involution on the abundance of Akt.
Therefore, the densitometric data for day of involution were collapsed
within each genotype/involution combination to allow statistical
analysis of treatment effects. This analysis demonstrated that the
overall abundance of phospho-Akt was decreased (P <
0.05) in forced involution to only 12% of that observed during natural
involution (Fig. 7B
). Overall abundance of total Akt during forced
involution was decreased (P < 0.05) to 33% of that
observed during natural involution (Fig. 7C
). The enhancement
(P < 0.05) of phospho-Akt in WAP-DES mice during
forced involution, although statistically significant, was relatively
small compared to the overall reduction that was observed with forced
involution. In addition, this small, but statistically significant,
increase in phospho-Akt was not accompanied by a similarly significant
increase in total Akt. Like IRS-1 and -2, the decrease in Akt preceded
the onset of apoptosis during forced involution. Reprobing of the blots
demonstrated little effect of genotype or involution on K18
abundance.
 |
Discussion
|
|---|
This study demonstrates that overexpression of des(1, 2, 3)IGF-I has
a differential capacity to inhibit apoptosis in the involuting mammary
gland depending on whether the involution is allowed to occur
naturally or is forced. This differential response could be the result
of a number of phenomena. These include decreased concentrations,
bioavailability or bioactivity of des(1, 2, 3)IGF-I during forced
involution, or decreased responsiveness of the mammary epithelium
to des(1, 2, 3)IGF-I during force involution.
The direct measurement of des(1, 2, 3)hIGF-I concentrations demonstrate
that the tissue concentrations present in the mammary glands of the
WAP-DES mice during forced involution are essentially the same as those
observed during natural involution, with the exception of elevated
concentrations on day 22. Although this elevation on day 22 is
counterintuitive and currently unexplained, it also probably has little
relevance to the apoptotic processes that began on days 1820
postpartum. The concentrations of des(1, 2, 3)hIGF-I are much higher than
those of endogenous IGF-I and are probably more than adequate to
stimulate a responsive epithelium. Because the des(1, 2, 3)IGF-I analog
expressed by the WAP-DES transgene has reduced affinity for all
IGFBPs (24, 25, 26), reduced bioavailability through
interaction with IGFBPs seems unlikely. The present studies cannot,
however, rule out the possibility that the differential ability of
WAP-DES to inhibit apoptosis is due to decreased bioactivity during
forced involution. Despite this caveat, we believe that the data
strongly implicate the third possibility, that mammary epithelial cells
lose their responsiveness to IGF signals during the early stages of
forced involution.
The IRS proteins have been shown to mediate proliferative and
antiapoptotic responses in a number of different
insulin/IGF-I-responsive cell types and tissues, including breast tumor
cells (20, 27, 28). Analyses of the tyrosine
phosphorylation state of IGF-IR or signaling molecules such as IRS-1
would presumably serve as a meaningful indicator of IGF-I bioactivity
based on cell culture models (29). Although the procedures
used in these studies were not sensitive enough to detect
phosphorylated IGF-IR in involuting mammary tissue extracts,
phosphorylation of IRS-1, IRS-2, and Akt was detectable. The fact that
the phosphorylation state of these molecules showed only modest
increases in the pooled extracts from WAP-DES mice was probably due to
high background phosphorylation in those derived from the
nontransgenics. In addition to phosphorylation by insulin or IGF-I
receptors, IRS-1 and -2 could serve as substrates for JAK2-dependent
phosphorylation in response to PRL or GH stimulation (30).
Importantly, the level of tyrosine phosphorylation of IRS-1 declined
significantly with the onset of forced involution. This decline was
associated not with decreased IGF-IR abundance, but with a decrease in
the abundance of IRS-1 protein. The ability to detect IRS-2
phosphorylation during forced, but not natural, involution is somewhat
puzzling and remains unexplained. However, like IRS-1, a dramatic loss
of IRS-2 protein occurred with the onset of forced involution.
The dramatic decrease in phospho-Akt levels during forced involution
correlated with the decline in IRS-1 and -2 phosphorylation and
expression and was only partially explained by a decrease in the
abundance of Akt protein. This decrease is consistent with previous
reports demonstrating IRS dependence of Akt phosphorylation (12, 22, 23). The presence of detectable phospho-Akt in mammary
extracts during forced involution in the absence of detectable IRS
phosphorylation, however, supports the possibility that other factors
can mediate Akt phosphorylation in the absence of IRS proteins. The
observation that phospho-Akt was higher in extracts prepared from
WAP-DES mice during forced involution suggests that these other factors
may be capable of mediating an IGF signal. The integrin-linked kinase
has been shown to phosphorylate and activate Akt in an
insulin-dependent, PI3 kinase-dependent, fashion (31).
These potential IRS-independent mechanisms, however, must serve a
relatively minor role, because the most dramatic changes in Akt
phosphorylation correlated with the loss of IRS-1. During the course of
these studies an attempt was also made to measure the abundance of both
BAD and phospo-BAD as a means of determining whether the apoptotic
pathway downstream of Akt was also decreased during force involution.
These attempts were unsuccessful due to sensitivity limitations of the
available antibodies.
The interpretation of the differences between forced and natural
involution with respect to IRS-1, IRS-2, and Akt abundance must include
two important considerations. Firstly, these decreases occurred during
a time when the mammary gland undergoes significant epithelial cell
loss. The wet weight data in Fig. 1
illustrates this loss and agrees
with previously published morphometric data that suggest that over the
course of 6 days of forced involution the mammary gland loses about
half of its epithelial cell population (10). On this
basis, the abundance of epithelial markers such as K18 would be
expected to change by 2-fold at most. The small changes in K18
abundance after 4 days of involution in the present study agree with
previously published results (10), which showed only
minimal changes in K18 abundance over 6 days of forced involution. This
is probably due to the fact that despite losses over 46 days of
involution the epithelium remain the predominant contributor on a mass
basis to the protein that would be obtained from a whole gland lysate.
Hence the loss of epithelium that occurs during forced involution is
far too small to account for the 10-fold loss in IRS-1, IRS-2, and
phospho-Akt. The second consideration in the comparison of natural with
forced involution is the potential for differences to exist in the rate
of epithelial cell loss between the two paradigms. Although direct
comparisons between forced and natural involution in the mouse are
limited (1), studies of lactation in a variety of species
support the suggestion that the main difference between the two
paradigms is the occurrence of transient alveolar, distension, and
diminished secretion of galactopoietic hormones (32). Data
from the present study demonstrate that overall mammary gland weight
loss during the 4 days of forced involution was similar to that which
occurred over 6 days of natural involution. Hence, the daily rate of
epithelial loss during natural involution could be estimated to be
about 66% of that observed with forced involution. This observation
coupled with the finding that K18 abundance showed little systematic
change between natural and forced involution support the conclusion
that epithelial cell loss does not account for the dramatic differences
in the abundance of IRS-1, IRS-2, and phospho-Akt. The
immunohistochemical staining for IRS-1 (Fig. 5
) supports the conclusion
that the decreased IRS-1 detected by Western blotting is predominantly
due to decreased expression of IRS-1 in the epithelium. This conclusion
does not imply that IRS-1 is not expressed in adipocytes of the mammary
gland. In fact, immunohistochemical staining suggests that it is
expressed in mammary adipocytes (data not shown). However, as greater
than 97% of a typical adipocyte consists of either lipid or water, the
actual contribution of mammary adipocytes to the total protein present
in the whole gland lysates analyzed in these studies is probably small
(33). In addition, the increase in adipocyte number or
volume during involution is not associated with an increase in IRS-1
expression, suggesting that adipocytes are probably not the predominant
cell type responsible for the loss in IRS-1 expression in the present
studies.
The observation that IRS-1 and -2 mRNA abundance does not change with
forced involution supports the conclusion that these decreases in IRS-1
and -2 are due to changes in protein turnover and that the regulation
of IRS proteins in the mammary gland in vivo differs from
the steroid hormone-dependent regulation that has been documented in
cell culture models (20, 21). Immunohistochemistry
conducted on mammary tissue from mice undergoing either natural or
forced involution failed to detect the expression of ER
and PR. This
observation is consistent with the findings of previous studies of
estrogen and progesterone responsiveness of the mammary gland
(34) and supports the suggestion that the
steroid-dependent regulation of IRS mRNA abundance in not involved with
the loss of IRS during mammary involution. Instead, altered IRS protein
turnover analogous to a proteasome-dependent mechanism that has
recently been described in several cell types (35, 36) is
a more likely mechanism. Investigation of this possibility is currently
in progress.
In summary, these studies highlight the existence of mechanistic
differences between the regulation of natural and forced mammary gland
involution and suggest an important role for key members of the IGF
signaling pathway in the maintenance of IGF-I-dependent mammary cell
survival. Further studies using animal models with targeted alterations
in these signaling molecules will determine the mechanistic importance
of IRS expression to mammary gland involution.
 |
Acknowledgments
|
|---|
The authors thank Liz Hopkins for processing the tissue
sections, Louise Hadsell for help in enumerating the TUNEL results,
Nicholas Sassin for help in the analysis of tissue IGF-I
concentrations, Sharon Bonnette for help with the IRS RPA, and Ping
Zhang for help with the immunoblots. The authors also thank Dr. D.
C. Allred and his staff for performing the immunohistochemistry for
IRS-1, ER
, and PR. Thanks to Drs. Doug Burrin, Jeff Rosen, and Dan
Medina for critical review of the manuscript.
 |
Footnotes
|
|---|
1 This work was supported by NIH Grant DK-52197-01 and USDA
Cooperative Agreement 58-62550-6-001. This work is a publication of the
USDA/ARS Childrens Nutrition Research Center, Department of
Pediatrics, Baylor College of Medicine and Texas Childrens Hospital
(Houston, TX). The contents of this publication do not necessarily
reflect the views or policies of the USDA, nor does the mention of
trade names, commercial products, or organizations imply endorsement by
the U.S. government. 
2 Recipient of a Susan G. Komen Foundation Research Award. 
Received September 8, 2000.
 |
References
|
|---|
-
Quarrie LH, Addey CV, Wilde CJ 1996 Programmed
cell death during mammary tissue involution induced by weaning, litter
removal, and milk stasis. J Cell Physiol 168:559569[CrossRef][Medline]
-
Marti A, Lazar H, Ritter P, Jaggi R 1999 Transcription factor activities and gene expression during mouse
mammary gland involution. J Mammary Gland Biol Neoplasia 4:145152[CrossRef][Medline]
-
Lund LR, Romer J, Thomasset N, Solberg H, Pyke C,
Bissell MJ, Dano K, Werb Z 1996 Two distinct phases of apoptosis
in mammary gland involution: proteinase-independent and -dependent
pathways. Development 122:181193[Abstract]
-
Schorr K, Li M, Krajewski S, Reed JC, Furth PA 1999 Bcl-2 gene family and related proteins in mammary gland involution
and breast cancer. J Mammary Gland Biol Neoplasia 4:153164[CrossRef][Medline]
-
Jerry DJ, Kuperwasser C, Downing SR, Pinkas J, He C,
Dickinson E, Marconi S, Naber SP 1998 Delayed involution of the
mammary epithelium in BALB/c-p53null mice. Oncogene 17:23052312[CrossRef][Medline]
-
Travers MT, Barber MC, Tonner E, Quarrie L, Wilde CJ,
Flint DJ 1996 The role of prolactin and growth hormone in the
regulation of casein gene expression and mammary cell survival:
relationships to milk synthesis and secretion. Endocrinology 137:15301539[Abstract]
-
Feng Z, Marti A, Jehn B, Altermatt HJ, Chicaiza G,
Jaggi R 1995 Glucocorticoid and progesterone inhibit involution
and programmed cell death in the mouse mammary gland. J Cell Biol 131:10951103[Abstract/Free Full Text]
-
Tonner E, Quarrie L, Travers M, Barber M, Logan A,
Wilde C, Flint D 1995 Does an IGF-binding protein (IGFBP) present
in involuting rat mammary gland regulate apoptosis? Prog Growth Factor
Res 6:409414[CrossRef][Medline]
-
Tonner E, Barber MC, Travers MT, Logan A, Flint DJ 1997 Hormonal control of insulin-like growth factor-binding protein-5
production in the involuting mammary gland of the rat. Endocrinology 138:51015107[Abstract/Free Full Text]
-
Chapman RS, Lourenco PC, Tonner E, Flint DJ, Selbert S,
Kiyoshi T, Akira S, Clarke AR, Watson CJ 1999 Suppression of
epithelial apoptosis and delayed mammary gland involution in mice with
a conditional knockout of stat3. Genes Dev 13:26042616[Abstract/Free Full Text]
-
Dews M, Nishimoto I, Baserga R 1997 IGF-I receptor
protection from apoptosis in cells lacking the IRS proteins. Recept
Signal Transduct 7:231240[Medline]
-
Yenush L, Zanella C, Uchida T, Bernal D, White MF 1998 The pleckstrin homology and phosphotyrosine binding domains of
insulin receptor substrate 1 mediate inhibition of apoptosis by
insulin. Mol Cell Biol 18:67846794[Abstract/Free Full Text]
-
Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y,
Greenberg ME 1997 Akt phosphorylation of BAD couples survival
signals to the cell-intrinsic death machinery. Cell 91:231241[CrossRef][Medline]
-
Neuenschwander S, Schwartz A, Wood TL, Roberts CT, Jr,
Hennighausen L, LeRoith D 1996 Involution of the lactating mammary
gland is inhibited by the IGF system in a transgenic mouse model.
J Clin Invest 97:22252232[Medline]
-
Hadsell DL, Greenberg NM, Fligger JM, Baumrucker CR,
Rosen JM 1996 Targeted expression of des(13) human insulin-like
growth factor I in transgenic mice influences mammary gland development
and IGF-binding protein expression. Endocrinology 137:321330[Abstract]
-
Hadsell DL, Murphy KL, Reece N, Alexeenko T, Lascerica
R, Rosen JM 2000 Cooperation between des(13)IGF-I and mutant p53
accelerates mammary gland carcinogenesis in bigenic mice. Oncogene 19:889898[CrossRef][Medline]
-
Li B, Murphy KL, Laucirica R, Kittrell F, Medina D,
Rosen JM 1998 A transgenic mouse model for mamary carcinogenesis.
Oncogene 16:9971007[CrossRef][Medline]
-
Gavrieli Y, Sherman Y, Ben-Sasson SA 1992 Identification of programmed cell death in situ via specific labeling
of nuclear DNA fragmentation. J Cell Biol 119:493501[Abstract/Free Full Text]
-
DErcole AJ, Stiles AD, Underwood LE 1984 Tissue
concentrations of somatomedin C: further evidence for multiple sites of
synthesis and paracrine or autocrine mechanisms of action. Proc Natl
Acad Sci USA 81:935939[Abstract/Free Full Text]
-
Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG,
Coronado-Heinsohn E, Osborne CK, Yee D 1999 Enhancement of
insulin-like growth factor signaling in human breast cancer: estrogen
regulation of insulin receptor substrate-1 expression in
vitro and in vivo. Mol Endocrinol 13:787796[Abstract/Free Full Text]
-
Vassen L, Wegrzyn W, Klein-Hitpass L 1999 Human
insulin receptor substrate-2 (IRS-2) is a primary progesterone response
gene. Mol Endocrinol 13:485494[Abstract/Free Full Text]
-
Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper
GM, Segal RA, Kaplan DR, Greenberg ME 1997 Regulation of neuronal
survival by the serine-threonine protein kinase Akt. Science 275:661664[Abstract/Free Full Text]
-
Franke TF, Kaplan DR, Cantley LC, Toker A 1997 Direct regulation of the Akt proto-oncogene product by
phosphatidylinositol-3,4-bisphosphate. Science 275:665667[Abstract/Free Full Text]
-
Clemmons DR, Dehoff MH, Busby WH, Bayne ML, Cascieri
MA 1992 Competition for binding to insulin-like growth factor
(IGF) binding protein-2, 3, 4, and 5 by IGFs and IGF analogs.
Endocrinology 131:890895[Abstract]
-
Oh Y, Muller HL, Lee DY, Fielder PJ, Rosenfeld RG 1993 Characterization of the affinities of insulin-like growth factor
(IGF)-binding proteins 14 for IGF-I, IGF-II, IGF-I/insulin hybrid,
and IGF-I analogs. Endocrinology 132:13371344[Abstract]
-
Wong MS, Fong CC, Yang M 1999 Biosensor measurment
of the interaction kinetics between insulin-like growth factors and
their binding proteins. Biochim Biophys Acta 1432:293301[CrossRef][Medline]
-
Guvakova MA, Surmacz E 1997 Tamoxifen interferes
with the insulin-like growth factor I receptor (IGF-IR) signaling
pathway in breast cancer cells. Cancer Res 57:26062610[Abstract/Free Full Text]
-
Ando S, Panno ML, Salerno M, Sisci D, Mauro L, Lanzino
M, Surmacz E 1998 Role of IRS-1 in insulin-induced modulation of
estrogen receptors in breast cancer cells. Biochem Biophys Res Commun 253:315319[CrossRef][Medline]
-
Myers MGJ, Sun XJ, Cheatham B, Jachna BR, Glasheen EM,
Backer JM, White MF 1993 IRS-1 is a common element in insulin and
insulin-like growth factor-I signaling to the phosphatidylinositol 3'
kinase. Endocrinology 132:14211430[Abstract]
-
Yamauchi T, Kaburagi Y, Ueki K, Tsuji Y, Stark GR, Kerr
IM, Tsushima T, Akanuma Y, Komuro I, Tobe K, Yazaki Y, Kadowaki T 1998 Growth hormone and prolactin stimulate tyrosine phosphorylation of
insulin receptor substrate-1, -2, and -3, their association with p85
phosphatidylinositol 3-kinase (PI3-kinase), and concomitantly
PI3-kinase activation via JAK2 kinase. J Biol Chem 273:1571915726[Abstract/Free Full Text]
-
Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar
S 1998 Phosphoinositide-3-OH kinase-dependent regulation of
glycogen synthase kinase 3 and protein kinase B/AKT by the
integrin-linked kinase. Proc Natl Acad Sci USA 95:1121111216[Abstract/Free Full Text]
-
Wilde CJ, Knight CH, Flint DJ 1999 Control of milk
secretion and apoptosis during mammary involution. J Mammary Gland Biol
Neoplasia 4:129136[CrossRef][Medline]
-
DiGirolamo M, Owens JL 1976 Water content of rat
adipose tissue and isolated adipocytes in relation to cell size.
Am J Physiol 231:15681572[Abstract/Free Full Text]
-
Shyamala G, Schneider W, and Schott D 1990 Developmental regulation of murine mammary progesterone receptor gene
expression. Endocrinology 126:28822889[Abstract]
-
Sun XJ, Goldberg JL, Qiao LY, Mitchell JJ 1999 Insulin-induced insulin receptor substrate-1 degradation is mediated by
the proteosomal degradaiont pathway. Diabetes 48:13591364[Abstract]
-
Lee AV, Gooch JL, Oesterreich S, Guler RL, Yee D 2000 Insulin-like growth factor I-induced degradation of insulin
receptor substrate 1 is mediated by the 26s proteosome and blocked by
phosphatidylinositol 3'-kinase inhibition. Mol Cell Biol 20:14891496[Abstract/Free Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
D. L Hadsell, A. F Parlow, D. Torres, J. George, and W. Olea
Enhancement of maternal lactation performance during prolonged lactation in the mouse by mouse GH and long-R3-IGF-I is linked to changes in mammary signaling and gene expression
J. Endocrinol.,
July 1, 2008;
198(1):
61 - 70.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. L Hadsell, W. Olea, N. Lawrence, J. George, D. Torres, T. Kadowaki, and A. V Lee
Decreased lactation capacity and altered milk composition in insulin receptor substrate null mice is associated with decreased maternal body mass and reduced insulin-dependent phosphorylation of mammary Akt
J. Endocrinol.,
August 1, 2007;
194(2):
327 - 336.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. McDaniel, K. K. Rumer, S. L. Biroc, R. P. Metz, M. Singh, W. Porter, and P. Schedin
Remodeling of the Mammary Microenvironment after Lactation Promotes Breast Tumor Cell Metastasis
Am. J. Pathol.,
February 1, 2006;
168(2):
608 - 620.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. L. Hadsell, D. T. Torres, N. A. Lawrence, J. George, A. F. Parlow, A. V. Lee, and M. L. Fiorotto
Overexpression of Des(1-3) Insulin-Like Growth Factor 1 in the Mammary Glands of Transgenic Mice Delays the Loss of Milk Production with Prolonged Lactation
Biol Reprod,
December 1, 2005;
73(6):
1116 - 1125.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. L. Annen, R. J. Collier, M. A. McGuire, and J. L. Vicini
Effects of Dry Period Length on Milk Yield and Mammary Epithelial Cells
J Dairy Sci,
July 1, 2004;
87(13_suppl):
E66 - 76.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. A. Green, M. J. Naylor, E. T. Lowe, P. Wang, E. Marshman, and C. H. Streuli
Caspase-mediated Cleavage of Insulin Receptor Substrate
J. Biol. Chem.,
June 11, 2004;
279(24):
25149 - 25156.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Allar and T. L. Wood
Expression of the Insulin-Like Growth Factor Binding Proteins during Postnatal Development of the Murine Mammary Gland
Endocrinology,
May 1, 2004;
145(5):
2467 - 2477.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. L. Hadsell, S. Bonnette, J. George, D. Torres, Y. Klementidis, S. Gao, P. M. Haney, J. Summy-Long, M. S. Soloff, A. F. Parlow, et al.
Diminished Milk Synthesis in Upstream Stimulatory Factor 2 Null Mice Is Associated With Decreased Circulating Oxytocin and Decreased Mammary Gland Expression of Eukaryotic Initiation Factors 4E and 4G
Mol. Endocrinol.,
November 1, 2003;
17(11):
2251 - 2267.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. V. Lee, P. Zhang, M. Ivanova, S. Bonnette, S. Oesterreich, J. M. Rosen, S. Grimm, R. C. Hovey, B. K. Vonderhaar, C. R. Kahn, et al.
Developmental and Hormonal Signals Dramatically Alter the Localization and Abundance of Insulin Receptor Substrate Proteins in the Mammary Gland
Endocrinology,
June 1, 2003;
144(6):
2683 - 2694.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. V. Lee, R. Schiff, X. Cui, D. Sachdev, D. Yee, A. P. Gilmore, C. H. Streuli, S. Oesterreich, and D. L. Hadsell
New Mechanisms of Signal Transduction Inhibitor Action: Receptor Tyrosine Kinase Down-Regulation and Blockade of Signal Transactivation
Clin. Cancer Res.,
January 1, 2003;
9(1):
516S - 523S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. L. Grimm, T. N. Seagroves, E. B. Kabotyanski, R. C. Hovey, B. K. Vonderhaar, J. P. Lydon, K. Miyoshi, L. Hennighausen, C. J. Ormandy, A. V. Lee, et al.
Disruption of Steroid and Prolactin Receptor Patterning in the Mammary Gland Correlates with a Block in Lobuloalveolar Development
Mol. Endocrinol.,
December 1, 2002;
16(12):
2675 - 2691.
[Abstract]
[Full Text]
[PDF]
|
 |
|